Latest Breaking News On - Innovent or company - Page 1 : comparemela.com

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

Rhui zhouUnited statesHong kongSanofi incyteEli lillyWei liInnovent biologicsCaicun zhouChina national medical products administrationMd anderson cancer centerDrug administrationNational medical products administrationInnovent or companyDepartment of oncology at shanghai east hospitalTongji universityInnovent biologics inc

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Rhui zhouHong kongUnited statesEli lillyInnovent biologicsCaicun zhouSanofi incyteWei liDrug administrationNational medical products administrationDepartment of oncology at shanghai east hospitalInnovent or companyTongji universityChina national medical products administrationMd anderson cancer centerAmerican society of clinical oncology

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18 2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

Rhui zhouUnited statesInnovent biologicsHana claudinEli lillyXianjun yuSanofi incyteInnovent or companyNational medical products administrationAmerican society of clinical oncologyGastrointestinal cancers congressInnovent biologics incFudan university shanghai cancer centerPrnewswire innovent biologics incBiliary cancer working groupMd anderson cancer center

Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma

Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongRhui zhouUnited statesInnovent biologicsChunrui liJinhua zhangAdimab incyteEli lillyEquecabtagene autoleucelLugui qiuPrnewswire innovent biologics incHuazhong university of science technologyChina national medical products administrationMd anderson cancer centerChinese academy of medical science hematology hospitalInnovent biologics inc

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongMccormick placeInnovent biologicsAdimab incyteEli lillyLugui qiuEquecabtagene autoleucel innoventEquecabtagene autoleucelChunrui liInnovent or companyChina national medical products administrationHuazhong university of science technologyMd anderson cancer centerPrnewswire innovent biologics incTongji medical college